马来酸罗格列酮治疗2型糖尿病的临床疗效观察  

Clinical study of Rosiglitazone(Avandia) in treating type 2 diabetes mellitus.

作　　者：李伟[1] 吴桐[1] 蒲琳[1] 王汝莲[1] 张勤[1] 

机构地区：[1]成都市第一人民医院,四川成都610016

出　　处：《四川医学》2002年第9期888-890,共3页Sichuan Medical Journal

摘　　要：目的　对新型口服降糖药 -马来酸罗格列酮 (文迪雅 )单用或与二甲双胍 /磺酰脲类合用临床疗效及安全性进行观察。方法　 4 6例 2型糖尿病患者进行为期 12周的文迪雅治疗的观察。包括单一用药组 (12例 ) ,合并二甲双胍组(16例 ) ,合并磺酰脲组 (18例 )。结果　与基线期相比 ,文迪雅治疗 12周后患者空腹血糖 (FBG)、糖化血红蛋白(Hb A1c)、空腹胰岛素 (FINS)水平均有显著下降 ,胰岛素抵抗指数 (HOMA指数 )下降。治疗后体重略有增加 ,总胆固醇(TC)、高密度脂蛋白 (HDL - C)、低密度脂蛋白 (L DL - C)有增加 ;收缩压和舒张压有降低。结论　文迪雅是胰岛素增敏剂 ,有明显的降低 2型糖尿病患者 FBG、FINS、Hb Alc,减少胰岛素抵抗的效果 ,是Objective To observe the clinical effcacy and safety of a new type of oral rosiglitazone(RSG)monotherapy or combination with metformin or sulphonyluea on patients with type 2 diabetes mellitus(DM).Methods 46 type 2 diabetic patients with mean baseline HbA1c≥7.5% on oral monotherapy with either metformin or a sulphoylurea,or only lifestyle interventions were divided into three groups,all of them were assigned to receive RSG at doses of 4 mg for 12 weeks.Results RSG used alone or in combination with metformin or sulphonylureas significantly reduced fasting plasma glucose(FBG)and fasting plasma insulin(FINS),and mean glycosylated hemoglobin values were significantly lower.Homeostasis model assessment indicated that RSG reduced insulin resistance. Body weight index(BMI)had an increase trend in the three groups but there were no significiant differences between them. In all RSG groups,the plasma levels of total cholesterol(TC),high density lipoprotein cholesterol(HDL C)and low density lipoprotein cholesterol(LDL C)increased significiantly.There were statistically significiant decreases in systolic blood presure (SBP) and diastolic blood pressure(DBP).No significant side effects on kidney and liver function were found.Conclusion Rosiglitazone is an insulin sensitizer that is effective and safe in patients with type 2 diabetes mellitus.

关 键 词：马来酸罗格列酮 治疗 2型糖尿病 疗效 文迪雅 降糖药 

分 类 号：R587.1[医药卫生—内分泌]